Skip Navigation


Rheumatology Advance Access originally published online on May 22, 2009
Rheumatology 2009 48(8):1012-1013; doi:10.1093/rheumatology/kep126
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/8/1012    most recent
kep126v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Iwata, S.
Right arrow Articles by Tanaka, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwata, S.
Right arrow Articles by Tanaka, Y.
Related Collections
Right arrow Vasculitis
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Letters to the Editor

Effects of anti-TNF-{alpha} antibody infliximab in refractory entero-Behçet's disease

Shigeru Iwata1, Kazuyoshi Saito1, Kunihiro Yamaoka1, Shizuyo Tsujimura1, Masao Nawata1, Katsunori Suzuki1 and Yoshiya Tanaka1

1The First Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan

Correspondence to: Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan. E-mail: tanaka@med.uoeh-u.ac.jp

The first 10% of the full text of this article appears below.

SIR, Entero-Behçet's disease (BD) is complicated by serious comorbidity, such as gastrointestinal bleeding and perforation, resulting in poor prognosis. Although high-dose corticosteroids (CSs) and immunosuppressants are widely used for treatments, refractory entero-BD is difficult to be managed, and effective treatment remains elusive. Therefore, there is a high priority for finding new treatments that promise a better outcome.

The study subjects were 10 patients who had been diagnosed previously with BD based on the criteria recommended by the International Study . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?